{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:56:39Z","timestamp":1762505799096},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T00:00:00Z","timestamp":1311897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00108-011-2896-2","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T09:13:16Z","timestamp":1311757996000},"page":"1359-1364","source":"Crossref","is-referenced-by-count":7,"title":["Neue Tyrosinkinase- und EGFR-Inhibitoren in der Tumortherapie"],"prefix":"10.1007","volume":"52","author":[{"given":"L.M.","family":"Ehmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,29]]},"reference":[{"key":"2896_CR1","first-page":"3010","volume":"7","author":"Babl","year":"2011","unstructured":"Babl J (2011) Hanf\u00f6lcreme nach Staehler. DAZ 7:3010\u20133014","journal-title":"DAZ"},{"key":"2896_CR2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358:1109\u20131117","journal-title":"N Engl J Med"},{"key":"2896_CR3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","volume":"23","author":"Chung","year":"2005","unstructured":"Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803\u20131810","journal-title":"J Clin Oncol"},{"key":"2896_CR4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1468-3083.2009.03516.x","volume":"24","author":"Eames","year":"2010","unstructured":"Eames T, Grabein B, Kroth J et al (2010) Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 24:958\u2013960","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2896_CR5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2340\/00015555-0792","volume":"90","author":"Eames","year":"2010","unstructured":"Eames T, Kroth J, Flaig MJ et al (2010) Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 90:202\u2013203","journal-title":"Acta Derm Venereol"},{"key":"2896_CR6","first-page":"1","volume":"16","author":"Ehmann","year":"2011","unstructured":"Ehmann LM, Ruzicka T, Wollenberg A (2011) Cutaneous side-effects of EGFR inhibitors and their management. Skin Therapy Lett 16:1\u20133","journal-title":"Skin Therapy Lett"},{"key":"2896_CR7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00105-010-1943-6","volume":"61","author":"Gerber","year":"2010","unstructured":"Gerber PA, Buhren BA, Kurle S et al (2010) Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors. Spektrum kutaner Nebenwirkungen. Hautarzt 61:654\u2013661","journal-title":"Hautarzt"},{"key":"2896_CR8","first-page":"195","volume":"9","author":"Gutzmer","year":"2011","unstructured":"Gutzmer R, Becker JC, Enk A et al (2011) Management of cutaneous side effects of EGRF inhibitors: recommendations from a German expert panel for the primary treating physican. J Dtsch Dermatol Ges 9:195\u2013203","journal-title":"J Dtsch Dermatol Ges"},{"key":"2896_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","volume":"56","author":"Hu","year":"2007","unstructured":"Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317\u2013326","journal-title":"J Am Acad Dermatol"},{"key":"2896_CR10","first-page":"232","volume":"105","author":"Ivanyi","year":"2008","unstructured":"Ivanyi P, Winkler T, Ganser A et al (2008) Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 105:232\u2013237","journal-title":"Dtsch Arztebl Int"},{"key":"2896_CR11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1684\/ejd.2010.0806","volume":"20","author":"Katzer","year":"2010","unstructured":"Katzer K, Tietze J, Klein E et al (2010) Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab \u2013 A report of 29 patients. Eur J Dermatol 20:82\u201384","journal-title":"Eur J Dermatol"},{"key":"2896_CR12","first-page":"559","volume":"15","author":"Klein","year":"2006","unstructured":"Klein E, Tietze J, Wollenberg A (2006) Unerw\u00fcnschte kutane Arzneimittelwirkungen von EGF-Rezeptor-Antagonisten und deren Behandlung. Allergo J 15:559\u2013565","journal-title":"Allergo J"},{"key":"2896_CR13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","volume":"56","author":"Kong","year":"2007","unstructured":"Kong HH, Cowen EW, Azad NS et al (2007) Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 56:171\u2013172","journal-title":"J Am Acad Dermatol"},{"key":"2896_CR14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","volume":"77","author":"Lipworth","year":"2009","unstructured":"Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77:257\u2013271","journal-title":"Oncology"},{"key":"2896_CR15","unstructured":"Lombardi G, Zustovich F, Donach M et al (2010) An update on targeted therapy in metastatic renal cell carcinoma. Urol Oncol [Epub ahead of print]"},{"key":"2896_CR16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jdermsci.2005.12.008","volume":"42","author":"Murata","year":"2006","unstructured":"Murata K, Sugita K, Kobayashi M et al (2006) Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes. J Dermatol Sci 42:91\u201399","journal-title":"J Dermatol Sci"},{"key":"2896_CR17","first-page":"abstr","volume":"20","author":"Ocvirk","year":"2008","unstructured":"Ocvirk J, Rebersek M (2008) Managing cutaneous side effects with K1 vitamine creme reduces cutaneous toxicities induced by cetuximab. J Clin Oncol 20 (Suppl):abstr 20750","journal-title":"J Clin Oncol"},{"key":"2896_CR18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdq387","volume":"22","author":"Potthoff","year":"2011","unstructured":"Potthoff K, Hofheinz R, Hassel JC et al (2011) Interdisciplinary management of EGFR inhibitor induced skin reactions: a German expert opinion. Ann Oncol 22:524\u2013535","journal-title":"Ann Oncol"},{"key":"2896_CR19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"Salomon","year":"1995","unstructured":"Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"key":"2896_CR20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201\u20131208","journal-title":"J Clin Oncol"},{"key":"2896_CR21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00002018-199614060-00003","volume":"14","author":"Sch\u00e4fer-Korting","year":"1996","unstructured":"Sch\u00e4fer-Korting M, Schmid MH, Korting HC (1996) Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Saf 14:375\u2013385","journal-title":"Drug Saf"},{"key":"2896_CR22","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol"},{"key":"2896_CR23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","volume":"3","author":"Segaert","year":"2005","unstructured":"Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599\u2013606","journal-title":"J Dtsch Dermatol Ges"},{"key":"2896_CR24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00120-005-0982-6","volume":"45","author":"Staehler","year":"2006","unstructured":"Staehler M, Haseke N, Schoppler G et al (2006) Therapiestrategien des fortgeschrittenen Nierenkarzinoms. Urologe A 45:99\u2013110","journal-title":"Urologe A"},{"key":"2896_CR25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00120-006-1211-7","volume":"45","author":"Staehler","year":"2006","unstructured":"Staehler M, Haseke N, Schoppler G et al (2006) Antiangiogenetische Therapie beim Nierenzellkarzinom. Management der Nebenwirkungen. Urologe A 45:1333\u20131342","journal-title":"Urologe A"},{"key":"2896_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","volume":"15","author":"Vincenzi","year":"2010","unstructured":"Vincenzi B, Santini D, Russo A et al (2010) Early skin toxicity as a predictive factor for tumor conrol in hepatocellular carcinoma patients treated with sorafenib. Oncologist 15:85\u201392","journal-title":"Oncologist"},{"key":"2896_CR27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0029-1244831","volume":"135","author":"Wollenberg","year":"2010","unstructured":"Wollenberg A, Kroth J, Hauschild A et al (2010) Hautreaktionen unter EGFR-Inhibitoren \u2013 Klinik und Management. Dtsch Med Wochenschr 135:149\u2013154","journal-title":"Dtsch Med Wochenschr"},{"key":"2896_CR28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","volume":"17","author":"Wollenberg","year":"2008","unstructured":"Wollenberg A, Moosmann N, Klein E et al (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17:790\u2013792","journal-title":"Exp Dermatol"},{"key":"2896_CR29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00105-006-1256-y","volume":"58","author":"Wollenberg","year":"2007","unstructured":"Wollenberg A, Moosmann N, Kroth J et al (2007) Therapie schwerer akneiformer Cetuximab-Exantheme mit oralem Retinoid, topischem Antibiotikum und Steroidexternum. Hautarzt 58:615\u2013618","journal-title":"Hautarzt"},{"key":"2896_CR30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s00105-010-1942-7","volume":"61","author":"Wollenberg","year":"2010","unstructured":"Wollenberg A, Staehler M, Eames T (2010) Kutane Nebenwirkungen der Multikinaseinhibitoren Sorafenib und Sunitinib. Hautarzt 61:662\u2013667","journal-title":"Hautarzt"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-011-2896-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-011-2896-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-011-2896-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T19:45:42Z","timestamp":1592768742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-011-2896-2"}},"subtitle":["Herz und Haut als wichtige Sch\u00e4digungsorgane. Teil B: Haut"],"short-title":[],"issued":{"date-parts":[[2011,7,29]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["2896"],"URL":"https:\/\/doi.org\/10.1007\/s00108-011-2896-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,29]]}}}